0001140361-21-017219 | 10-Q | XBRL Viewer

Document and Entity Information - shares	3 Months Ended
Document and Entity Information - shares	Mar. 31, 2021	May 07, 2021
Cover [Abstract]
Entity Registrant Name	NUWELLIS, INC.
Entity Central Index Key	0001506492
Current Fiscal Year End Date	--12-31
Document Type	10-Q
Amendment Flag	false
Document Quarterly Report	true
Document Period End Date	Mar. 31, 2021
Document Fiscal Year Focus	2021
Document Fiscal Period Focus	Q1
Entity Address, State or Province	MN
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		6,532,018

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2021	Dec. 31, 2020
Current assets
Cash and cash equivalents	$ 27,893	$ 14,437
Accounts receivable	919	905
Inventories	2,957	2,957
Other current assets	369	237
Total current assets	32,138	18,536
Property, plant and equipment, net	1,219	1,200
Operating lease right-of-use asset, net	206	255
Other assets	0	21
TOTAL ASSETS	33,563	20,012
Current liabilities
Accounts payable	1,613	1,097
Accrued compensation	1,245	2,192
Current portion of operating lease liability	212	206
Current portion of finance lease liability	24	24
Other current liabilities	69	66
Total current liabilities	3,163	3,585
Operating lease liability	0	55
Finance lease liability	48	54
Total liabilities	3,211	3,694
Commitments and contingencies
Stockholders' equity
Preferred stock	0	0
Common stock as of March 31, 2021 and December 31, 2020, par value $0.0001 per share; authorized 100,000,000 shares, issued and outstanding 6,531,942 and 2,736,060, respectively	0	0
Additional paid-in capital	268,921	249,663
Accumulated other comprehensive loss:
Foreign currency translation adjustment	(10)	(7)
Accumulated deficit	(238,559)	(233,338)
Total stockholders' equity	30,352	16,318
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	33,563	20,012
Series A Junior Participating Preferred Stock [Member]
Stockholders' equity
Preferred stock	0	0
Series F Convertible Preferred Stock [Member]
Stockholders' equity
Preferred stock	$ 0	$ 0

Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Condensed Consolidated Statements of Operations and Comprehensive Loss [Abstract]
Net sales	$ 1,918	$ 1,630
Cost of goods sold	952	796
Gross margin	966	834
Operating expenses:
Selling, general and administrative	5,237	4,537
Research and development	947	864
Total operating expenses	6,184	5,401
Loss from operations	(5,218)	(4,567)
Other income (expense), net	(1)	1
Loss before income taxes	(5,219)	(4,566)
Income tax expense	(2)	(2)
Net loss	$ (5,221)	$ (4,568)
Basic loss per share (in dollars per share)	$ (1.25)	$ (11.54)
Diluted loss per share (in dollars per share)	$ (1.25)	$ (11.54)
Weighted average shares outstanding - basic (in shares)	4,212	548
Weighted average shares outstanding - diluted (in shares)	4,212	548
Other comprehensive loss:
Foreign currency translation adjustments	$ (3)	$ (3)
Total comprehensive loss	$ (5,224)	$ (4,571)

Condensed Consolidated Statements of Stockholders' Equity - USD ($) $ in Thousands	Common Stock [Member]	Additional Paid in Capital [Member]	Accumulated Other Comprehensive Income [Member]	Accumulated Deficit [Member]	Total
Balance at Dec. 31, 2019	$ 0	$ 218,278	$ 1,214	$ (217,502)	$ 1,990
Balance (in shares) at Dec. 31, 2019	155,802
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss	$ 0	0	0	(4,568)	(4,568)
Foreign currency translation adjustments	0	0	(3)	0	(3)
Stock-based compensation and stock awards, net	$ 0	380	0	0	380
Stock-based compensation and stock awards, net (in shares)	0
Issuance of common and preferred stock, net	$ 0	9,616	0	0	9,616
Issuance of common and preferred stock, net (in shares)	340,261
Exercise of warrants	$ 0	289	0	0	289
Exercise of warrants (in shares)	29,933
Conversion of preferred stock into common stock	$ 0	0	0	0	0
Conversion of preferred stock into common stock (in shares)	378,751
Balance at Mar. 31, 2020	$ 0	228,563	1,211	(222,070)	7,704
Balance (in shares) at Mar. 31, 2020	904,747
Balance at Dec. 31, 2019	$ 0	218,278	1,214	(217,502)	1,990
Balance (in shares) at Dec. 31, 2019	155,802
Balance at Dec. 31, 2020	$ 0	249,663	(7)	(233,338)	16,318
Balance (in shares) at Dec. 31, 2020	2,736,060
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss	$ 0	0	0	(5,221)	(5,221)
Foreign currency translation adjustments	0	0	(3)	0	(3)
Stock-based compensation and stock awards, net	$ 0	355	0	0	355
Stock-based compensation and stock awards, net (in shares)	0
Issuance of common and preferred stock, net	$ 0	18,902	0	0	18,902
Issuance of common and preferred stock, net (in shares)	3,795,816
Exercise of warrants	$ 0	1	0	0	1
Exercise of warrants (in shares)	66
Balance at Mar. 31, 2021	$ 0	$ 268,921	$ (10)	$ (238,559)	$ 30,352
Balance (in shares) at Mar. 31, 2021	6,531,942

Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Operating Activities:
Net loss	$ (5,221)	$ (4,568)
Adjustments to reconcile net loss to cash flows used in operating activities:
Depreciation and amortization	126	65
Stock-based compensation expense, net	355	380
Loss on disposal of property and equipment	0	46
Changes in operating assets and liabilities:
Accounts receivable	(14)	72
Inventories	(89)	(398)
Other current assets	(132)	20
Other assets and liabilities	24	67
Accounts payable and accrued expenses	(431)	(1,179)
Net cash used in operating activities	(5,382)	(5,495)
Investing Activities:
Purchases of property and equipment	(56)	(17)
Net cash used in investing activities	(56)	(17)
Financing Activities:
Proceeds from public stock offerings, net	18,902	9,616
Proceeds from warrant exercises	1	289
Payments on finance lease liability	(6)	0
Net cash provided by financing activities	18,897	9,905
Effect of exchange rate changes on cash	(3)	(3)
Net increase in cash and cash equivalents	13,456	4,390
Cash and cash equivalents - beginning of period	14,437	1,279
Cash and cash equivalents - end of period	27,893	5,669
Supplemental cash flow information
Inventory transferred to property, plant and equipment	$ 89	$ 0

Nature of Business and Basis of Presentation

3 Months Ended

Mar. 31, 2021

Nature of Business and Basis of Presentation [Abstract]

Nature of Business and Basis of Presentation

Note 1 – Nature of Business and Basis of Presentation

Nature of Business: Nuwellis, Inc. (the “Company”) is a medical device company focused on developing, manufacturing and commercializing the Aquadex FlexFlow® and Aquadex SmartFlow® systems (collectively, the “Aquadex System”) for ultrafiltration therapy. The Aquadex System is indicated for temporary (up to eight hours) or extended (longer than 8 hours in patients who require hospitalization) use in adult and pediatric patients weighing 20kg or more whose fluid overload is unresponsive to medical management, including diuretics. Nuwellis, Inc. is a Delaware corporation headquartered in Minneapolis with a wholly owned subsidiary in Ireland. The Company’s common stock began trading on the Nasdaq Capital Market in February 2012.

In August 2016, the Company acquired the business associated with the Aquadex System (the “Aquadex Business”) from a subsidiary of Baxter International, Inc., and refocused its strategy to fully devote its resources to the Aquadex Business.

On April 27, 2021, the Company announced that it was changing its name from CHF Solutions, Inc. to Nuwellis, Inc. to more appropriately reflect the direction of its business.

Principles of Consolidation: The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 8 of Regulation S-X. Certain information and note disclosures normally included in the audited annual consolidated financial statements have been condensed or omitted pursuant to those rules and regulations. Accordingly, they do not include all of the information necessary for a fair presentation of results of operations, comprehensive loss, financial condition, and cash flows in conformity with U.S. GAAP. In the opinion of management, the condensed consolidated financial statements reflect all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation of the results of the Company for the periods presented. Operating results for interim periods are not necessarily indicative of results that may be expected for the year as a whole. The preparation of the financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues, expenses, and the related disclosures at the date of the financial statements and during the reporting period. Actual results could materially differ from these estimates.

For further information, refer to the consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2020.

Going Concern: The Company’s financial statements have been prepared and presented on a basis assuming it continues as a going concern. During the years ended December 31, 2020 and 2019 and through March 31, 2021, the Company incurred losses from operations and net cash outflows from operating activities as disclosed in the consolidated statements of operations and cash flows, respectively. As of March 31, 2021, the Company had an accumulated deficit of $238.6 million and it expects to incur losses for the immediate future. To date, the Company has been funded by debt and equity financings, and although the Company believes that it will be able to successfully fund its operations, there can be no assurance that it will be able to do so or that it will ever operate profitably.

The Company became a revenue generating company after acquiring the Aquadex Business in August 2016. The Company expects to incur additional losses in the near-term as it grows the Aquadex Business, including investments in expanding its sales and marketing capabilities, purchasing inventory, manufacturing components, and complying with the requirements related to being a U.S. public company. To become and remain profitable, the Company must succeed in expanding the adoption and market acceptance of the Aquadex System. This will require the Company to succeed in training personnel at hospitals and effectively and in efficiently manufacturing, marketing and distributing the Aquadex System and related components. There can be no assurance that the Company will succeed in these activities, and it may never generate revenues sufficient to achieve profitability.

During 2019, 2020 and through March 19, 2021, the Company closed on underwritten public equity offerings for aggregate net proceeds of approximately $57.6 million after deducting the underwriting discounts and commissions and other costs associated with the offerings (see Note 4 –Stockholders’ Equity). The Company will require additional funding to grow the Aquadex Business, which may not be available on terms favorable to the Company, or at all. The Company may receive those funds from the proceeds from future warrant exercises, issuances of equity securities, or other financing transactions.

The Company believes that its existing capital resources will be sufficient to support its operating plan through December 31, 2022. However, the Company may seek to raise additional capital to support its growth or other strategic initiatives through debt, equity or a combination thereof.

Revenue Recognition: The Company recognizes revenue in accordance with Accounting Standards Codification, Topic 606, Revenue from Contracts with Customers, which the Company adopted effective January 1, 2018. Accordingly, the Company recognizes revenue when its customers obtain control of its products or services, in an amount that reflects the consideration that the Company expects to receive in exchange for those goods and services. See Note 2 – Revenue Recognition below for additional disclosures. For the three months ended March 31, 2021, three customers represented 16%, 13% and 12% of net sales. For the three months ended March 31, 2020, three customers represented 15%, 13% and 10% of net sales.

Accounts Receivable: Accounts receivable are unsecured, are recorded at net realizable value, and do not bear interest. The Company makes judgments as to its ability to collect outstanding receivables based upon significant patterns of collectability, historical experience, and managements’ evaluation of specific accounts and will provide an allowance for credit losses when collection becomes doubtful. The Company performs credit evaluations of its customers’ financial condition on an as-needed basis. Payment is generally due 30 days from the invoice date and accounts past 30 days are individually analyzed for collectability. When all collection efforts have been exhausted, the account is written off against the related allowance. To date the Company has not experienced any write-offs or significant deterioration of the aging of its accounts receivable, and therefore, no allowance for doubtful accounts was considered necessary as of March 31, 2021 or December 31, 2020. As of March 31, 2021, one customer represented 12% of the accounts receivable balance. As of December 31, 2020, no customer represented over 10% of the accounts receivable balance.

Inventories: Inventories represent finished goods purchased from the Company’s supplier and are recorded as the lower of cost or net realizable value using the first-in-first out method. Overhead is allocated to manufactured finished goods inventory based on the normal capacity of the Company’s production facilities. Abnormal amounts of overhead, if any, are expensed as incurred. Inventories consisted of the following:

( in thousands)	March 31, 2021		December 31, 2020
Finished Goods	$	1,232	$	1,343
Work in Process		315		342
Raw Materials		1,410		1,272
Total	$	2,957	$	2,957

Loss per share: Basic loss per share is computed based on the net loss for each period divided by the weighted average number of common shares outstanding. The net loss allocable to common stockholders for the three months ended March 31, 2020, reflects a $1.8 million increase for the net deemed dividend to preferred stockholders provided in connection with the close of the public offering of Series H Convertible Preferred Stock on January 28, 2020. The deemed dividends represent the intrinsic value of the preferred shares at the time of issuance and includes $0.2 million that resulted from the subsequent change in the exercise price of the warrants as a result of the March 2020 offering. See Note 3 – Shareholders’ Equity below for additional disclosures. The net loss allocable to common stockholders for the three months ended March 31, 2021 includes a deemed dividend of $33,000 that resulted from the change in the exercise price of warrants as a result of the March 2021 offering.

Diluted earnings per share is computed based on the net loss allocable to common stockholders for each period divided by the weighted average number of common shares outstanding, increased by the number of additional shares that would have been outstanding had the potentially dilutive common shares been issued, and reduced by the number of shares the Company could have repurchased from the proceeds from issuance of the potentially dilutive shares. Potentially dilutive shares of common stock include shares underlying outstanding convertible preferred stock, warrants, stock options and other stock-based awards granted under stock-based compensation plans.

The following table sets forth the potential shares of common stock that are not included in the calculation of diluted net loss per share because to do so would be anti-dilutive as of the end of each period presented:

	March 31
	2021		2020
Warrants to purchase common stock		1,631,882		925,869
Series H convertible preferred stock		—		16,264
Series F convertible preferred stock		23,114		48,720
Stock options		140,471		13,995
Total		1,795,467		1,004,848

The following table reconciles reported net loss with reported net loss per share for each of the three months ended March 31:

(in thousands, except per share amounts)	2021			2020
Net loss	$	(5,221	)	$	(4,568	)
Deemed dividend to preferred shareholders (see Note 3)		(33	)		(1,757	)
Net loss after deemed dividend		(5,254	)		(6,325	)
Weighted average shares outstanding		4,212			548
Basic and diluted loss per share	$	(1.25	)	$	(11.54	)

The Company evaluates events through the date the consolidated financial statements are filed for events requiring adjustment to or disclosure in the consolidated financial statements.

Shareholders' Equity	3 Months Ended
Shareholders' Equity	Mar. 31, 2021
Shareholders' Equity [Abstract]
Shareholders' Equity	Note 3 – Shareholders’ Equity Series F Convertible Preferred Stock: On November 27, 2017, the Company closed on an underwritten public offering Series F convertible preferred stock and warrants to purchase shares of common stock for gross proceeds of $18.0 million. Net proceeds totaled approximately $16.2 million after deducting the underwriting discounts and commissions and other costs associated with the offering. The offering was comprised of Series F convertible preferred stock, convertible into shares of the Company’s common stock at an initial conversion price of $1,890.00 per share. Each share of Series F convertible preferred stock was accompanied by a Series 1 warrant, which was to expire on the first anniversary of its issuance, to purchase 16 shares of the Company’s common stock at an exercise price of $1,890.00 per share, and a Series 2 warrant, which expires on the seventh anniversary of its issuance, to purchase 16 shares of the Company’s common stock at an exercise price of $1,890.00 per share. The Series F convertible preferred stock has full ratchet price based anti-dilution protection, subject to customary carve outs, in the event of a down-round financing at a price per share below the conversion price of the Series F convertible preferred stock (which protection will expire if, during any 20 of 30 consecutive trading days, the volume weighted average price of the Company’s common stock exceeds 300% of the then-effective conversion price of the Series F convertible preferred stock and the daily dollar trading volume for each trading day during such period exceeds $200,000). The exercise price of the warrants is fixed and does not contain any variable pricing features, nor any price-based anti-dilutive features, apart from customary adjustments for stock splits, combinations, reclassifications, stock dividends or fundamental transactions. A total of 18,000 shares of Series F convertible preferred stock initially convertible into 9,557 shares of common stock and warrants to purchase 19,122 shares of common stock were issued in the offering. Effective March 12, 2019, the conversion price of the Series F convertible preferred stock was reduced from $890.40 to $157.50, the per share price to the public of the Series G convertible preferred stock issued in the March 2019 Offering, described below. Effective October 25, 2019, the conversion price of the Series F convertible preferred stock was reduced from $157.50 to $42.30, and on November 6, 2019 from $42.30 to $29.83, the per share price to the public in the October and November 2019 transactions, respectively, described below. Effective January 28, 2020, the conversion price of the Series F convertible preferred stock was reduced from $29.83 to $16.50, the per share price to the public of the Series H convertible preferred stock which closed in an underwritten public offering on January 28, 2020, described below. Effective March 23, 2020, the conversion price of the Series F convertible preferred stock was reduced from $16.50 to $9.00, the per share price to the public in the March 2020 offering, described below. As of March 31, 2021, and December 31, 2020, 127 shares of the Series F convertible preferred stock remained outstanding. Series G Convertible Preferred Stock and March 2019 Offering: On March 12, 2019, the Company closed on an underwritten public offering of common stock, Series G convertible preferred stock and warrants to purchase shares of common stock for gross proceeds of $12.4 million, which included the full exercise of the underwriter’s over-allotment option to purchase additional shares and warrants (“March 2019 Offering”). Net proceeds totaled approximately $11.0 million after deducting the underwriting discounts and commissions and other costs associated with the offering. The Series G convertible preferred stock included a beneficial conversion amount of $4.5 million, representing the intrinsic value of the shares at the time of issuance. This amount was reflected as an increase to the loss per share allocable to common stockholders in the year ended December 31, 2019. The March 2019 Offering was comprised of 15,173 shares of common stock priced at $157.50 per share and 1,910,536 shares of Series G convertible preferred stock, convertible into common stock at $157.50 per share. Each share of Series G convertible preferred stock and each share of common stock was accompanied by a Series 1 warrant and a Series 2 warrant. The Series 1 warrants are exercisable into 78,863 shares of common stock and the Series 2 warrants are exercisable into 78,863 shares of common stock. Series 1 warrants expire on the fifth anniversary of the date of issuance and are exercisable at $157.50 to purchase one share of common stock. Series 2 warrants expire on the earlier of: (i) the eighteen-month anniversary of the date of issuance and (ii) the 30th trading day following the public announcement of the receipt from the U.S. Food and Drug Administration (FDA) of clearance or approval of a modification to the product label for the Aquadex System to include pediatric patients. Series 2 warrants are exercisable at $157.50 per share of common stock. The Company announced it had received FDA clearance for use of its Aquadex System in pediatric patients on February 26, 2020, effectively setting the date of expiration of these warrants for April 8, 2020. The conversion price of the Series G convertible preferred stock as well as the exercise price of the warrants are fixed and do not contain any variable pricing features, nor any price based anti-dilutive features apart from customary adjustments for splits and reverse splits of common stock. The Series G convertible preferred stock included a beneficial ownership limitation of 4.99% but had no dividend preference (except to extent dividends are also paid on the common stock), liquidation preference or other preferences over common stock. The securities comprising the units were immediately separable and were issued separately. As of December 31, 2019, all 63,685 shares of the Series G convertible preferred stock had been converted into common stock and none remained outstanding. October and November 2019 Offerings: On October 25, 2019, the Company closed on a registered direct offering of 19,195 shares of common stock at a price of $34.50 per share, for gross proceeds of approximately $660,000, prior to deducting commissions and expenses related to the transaction. In a concurrent private placement, the Company agreed to issue to the investors in the registered direct offering unregistered warrants to purchase up to 19,196 shares of its common stock at an exercise price of $42.30 per share, which became exercisable six months from the date of issuance and will expire five years from the initial exercise date. On November 6, 2019, the Company closed on a registered direct offering of 40,637 shares of common stock, or common equivalents, at a price of $33.60 per share, for gross proceeds of approximately $1.36 million prior to deduction of commissions and offering expenses related to the transaction. In a concurrent private placement, the Company agreed to issue to the investors in the registered direct offering warrants to purchase up to 40,638 shares of our common stock at an exercise price of $29.83 per share, which were exercisable upon the date of issuance, and will expire five years from the initial exercise date. Series H Convertible Preferred Stock and January 2020 Offering: On January 28, 2020, the Company closed on an underwritten public offering of common stock, Series H convertible preferred stock and warrants to purchase shares of common stock for gross proceeds of $9.7 million, which included the full exercise of the underwriter’s over-allotment option to purchase additional shares and warrants (“January 2020 Offering”). Net proceeds totaled approximately $8.6 million after deducting the underwriting discounts and commissions and other costs associated with the offering. The Series H convertible preferred stock included a beneficial conversion amount of $1.6 million, representing the intrinsic value of the shares at the time of issuance, and $0.2 million of down-round protection in connection with the re-pricing of the warrants following the March 2020 offering described below. This amount is reflected as an increase to the loss per share allocable to common stockholders in the three months ended March 31, 2020. The January 2020 Offering was comprised of 201,546 shares of common stock priced at $16.50 per share and 11,517,269 shares of Series H convertible preferred stock, convertible into common stock at $16.50 per share, including the full exercise of the over-allotment option. Each share of Series H convertible preferred stock and each share of common stock was accompanied by a warrant to purchase common stock. The warrants are exercisable into 585,460 shares of common stock. The conversion price of the preferred stock issued in the transaction is fixed and does not contain any variable pricing feature or any price based anti-dilutive feature. The preferred stock issued in this transaction includes a beneficial ownership blocker but has no dividend rights (except to the extent that dividends are also paid on the common stock) or liquidation preference, and, subject to limited exceptions, has no voting rights. The securities comprising the units are immediately separable and were issued separately. The warrants were exercisable beginning on the closing date and expire on the fifth anniversary of the closing date and had an initial exercise price per share equal to $16.50 per share, subject to appropriate adjustment in the event of subsequent equity sales of common stock or securities convertible into common stock for an exercise price per share less than the exercise price per share of the warrants then in effect (but in no event lower than 10% of the applicable Unit offering price), or in the event of recapitalization events, stock dividends, stock splits, stock combinations, reclassifications, reorganizations or similar events affecting our common stock. Effective March 23, 2020, the exercise price of these warrants was reduced from $16.50 to $9.00, the per share price to the public in the March 2020 offering described below. Effective with the March 19, 2021 financing, the exercise price for the unexercised warrants from the January 2020 offering were further reduced to $5.50 per share. The net loss allocable to common stockholders for the three months ended March 31, 2021 includes a deemed dividend of $33,000 that resulted from the change in the exercise price of warrants as a result of the March 2021 offering. As of December 31, 2020, all 11,517,269 shares of the Series H convertible preferred stock had been converted into common stock and none remained outstanding. As of March 31, 2021, warrants to purchase 130,246 shares of common stock remain exercisable. March 2020 Offering: On March 23, 2020, the Company closed on a registered direct offering of 138,715 shares of its common stock at a price to the public of $9.00 per share, for gross proceeds of approximately $1.2 million, or $1.0 million net after deducting commissions and offering expenses. In a concurrent private placement, the Company agreed to issue to the investors in the registered direct offering warrants to purchase up to 138,715 shares of the Company’s common stock. The warrants to purchase up to 138,715 shares of common stock have an exercise price of $11.18 per share, were exercisable six months from the date of issuance, and will expire five and a half years from the date of issuance. April 2020 Offering: On April 1, 2020, the Company closed on a registered direct offering of 171,008 shares of its common stock at a price to the public of $13.02 per share, for gross proceeds of approximately $2.2 million, prior to deduction of commissions and offering expenses related to the transaction. In a concurrent private placement, the Company agreed to issue to the investors in the registered direct offering warrants to purchase up to 85,506 shares of the Company’s common stock. The warrants have an exercise price of $11.15 per share, were exercisable immediately, and will expire five and a half years from the date of issuance. May 2020 Offering: On May 5, 2020, the Company closed on a registered direct offering of 119,930 shares of its common stock at a price to the public of $14.18 per share, for gross proceeds of approximately $1.7 million, prior to deduction of commissions and offering expenses related to the transaction. In a concurrent private placement, the Company agreed to issue to the investors in the registered direct offering warrants to purchase up to 59,966 shares of the Company’s common stock. The warrants have an exercise price of $12.30 per share, were exercisable immediately, and will expire five and a half years from the date of issuance. August 2020 Offering: On August 21, 2020, the Company closed on an underwritten public offering of common stock and warrants to purchase shares of common stock for gross proceeds of approximately $14.4 million, which included the full exercise of the underwriter’s over-allotment option to purchase additional shares and warrants (“August 2020 Offering”). Net proceeds totaled approximately $13.0 million after deducting the underwriting discounts and commissions and other costs associated with the offering. The August 2020 Offering was comprised of 1,064,678 shares of common stock priced at $13.50 per share. Each share of common stock was accompanied by a warrant to purchase common stock. The warrants are exercisable into 1,064,678 shares of common stock. The securities comprising the units are immediately separable and were issued separately. The warrants were exercisable beginning on the effective date of our stockholders’ approval of a reverse stock split in an amount sufficient to permit the exercise in full of the warrants, which occurred on October 6, 2020, and will expire on the five-year anniversary of the closing date. March 2021 Offering: On March 19, 2021, the Company closed on an underwritten public offering of 3,795,816 shares of common stock, which includes the full exercise of the underwriters’ over-allotment option, for gross proceeds of approximately $20.9 million (the “March 2021 Offering”). Net proceeds totaled approximately $18.9 million after deducting the underwriting discounts and commissions and other costs associated with the offering and after giving effect to the underwriters’ full exercise of their overallotment option. In connection with the March 2021 Offering, the conversion price of the Series F convertible preferred stock was reduced from $9.00 to $5.50, the per share price to the public in the March 2021 Offering. In addition, the exercise price of the common stock warrants issued in connection with the January 2020 Offering was reduced from $9.00 to $5.50, the per share price to the public in the March 2021 Offering. Placement Agent Fees: In connection with the offerings described above, the Company paid the placement agent an aggregate cash placement fee equal to 8% of the aggregate gross proceeds raised in each of the offerings. Market-Based Warrants: On May 30, 2019, the Company granted a market-based warrant to a consultant in exchange for investor relations services. The warrant represents the right to acquire up to 3,334 shares of the Company’s common stock at an exercise price of $95.40 per share, the closing stock price of the Company’s common shares on May 30, 2019. The warrant is subject to a vesting schedule based on the Company achieving certain market stock prices within a specified period of time. The warrant expires on May 30, 2024. The warrant was valued at $57.90 per share using the Monte Carlo valuation methodology and was expensed over the term of the consulting engagement which was twelve months. Significant inputs used for the Monte Carlo valuation were the expected stock price volatility of 136.21%, and management’s expectations regarding the timing of regulatory clearance for an expanded label in pediatrics. None of these warrants had vested as of March 31, 2021.

Nature of Business and Basis of Presentation (Policies)

3 Months Ended

Mar. 31, 2021

Nature of Business and Basis of Presentation [Abstract]

Principles of Consolidation

For further information, refer to the consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2020.

( in thousands)	March 31, 2021		December 31, 2020
Finished Goods	$	1,232	$	1,343
Work in Process		315		342
Raw Materials		1,410		1,272
Total	$	2,957	$	2,957

Loss per Share

	March 31
	2021		2020
Warrants to purchase common stock		1,631,882		925,869
Series H convertible preferred stock		—		16,264
Series F convertible preferred stock		23,114		48,720
Stock options		140,471		13,995
Total		1,795,467		1,004,848

The following table reconciles reported net loss with reported net loss per share for each of the three months ended March 31:

(in thousands, except per share amounts)	2021			2020
Net loss	$	(5,221	)	$	(4,568	)
Deemed dividend to preferred shareholders (see Note 3)		(33	)		(1,757	)
Net loss after deemed dividend		(5,254	)		(6,325	)
Weighted average shares outstanding		4,212			548
Basic and diluted loss per share	$	(1.25	)	$	(11.54	)

- Definition

Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.

+ References + Details

- Definition

Disclosure of accounting policy for revenue from contract with customer.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 17
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130561-203045

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 20
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 18
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130563-203045

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-URI http://asc.fasb.org/topic&trid=49130388

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 20
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 18
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130563-203045

Reference 7: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 4
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18823-107790

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 20
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 19
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130564-203045

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 20
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045

+ Details

Nature of Business and Basis of Presentation, Nature of Business, Going Concern, Accounts Receivable and Inventories (Details) $ in Thousands		3 Months Ended		12 Months Ended
	Mar. 19, 2021 USD ($)	Mar. 31, 2021 USD ($) Customer	Mar. 31, 2020 USD ($) Customer	Dec. 31, 2020 USD ($) Customer
Going Concern [Abstract]
Accumulated deficit		$ (238,559)		$ (233,338)
Net proceeds from issuance of convertible preferred stock	$ 57,600
Proceeds from warrant exercises		$ 1	$ 289
Accounts Receivable [Abstract]
Accounts receivables maximum credit period from invoice date		30 days
Allowance for doubtful accounts		$ 0		0
Inventories [Abstract]
Finished Goods		1,232		1,343
Work in Process		315		342
Raw Materials		1,410		1,272
Total		$ 2,957		$ 2,957
Accounts Receivable [Member]
Revenue, Performance Obligation [Abstract]
Number of major customers \| Customer		1		0
Customer One [Member] \| Accounts Receivable [Member] \| Customer Concentration Risk [Member]
Revenue, Performance Obligation [Abstract]
Percentage of net sales		12.00%
ASC 606 [Member] \| Net Sales [Member]
Revenue, Performance Obligation [Abstract]
Number of major customers \| Customer		3	3
ASC 606 [Member] \| Customer One [Member] \| Net Sales [Member] \| Customer Concentration Risk [Member]
Revenue, Performance Obligation [Abstract]
Percentage of net sales		16.00%	15.00%
ASC 606 [Member] \| Customer Two [Member] \| Net Sales [Member] \| Customer Concentration Risk [Member]
Revenue, Performance Obligation [Abstract]
Percentage of net sales		13.00%	13.00%
ASC 606 [Member] \| Customer Three [Member] \| Net Sales [Member] \| Customer Concentration Risk [Member]
Revenue, Performance Obligation [Abstract]
Percentage of net sales		12.00%	10.00%

Nature of Business and Basis of Presentation, Loss Per Share (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Potential shares of common stock that are not included in the calculation of diluted net loss per share [Abstract]
Potential shares of common stock that are not included in the calculation of diluted net loss per share (in shares)	1,795,467	1,004,848
Reported net loss with reported net loss per share [Abstract]
Net loss	$ (5,221)	$ (4,568)
Deemed dividend to preferred shareholders (see Note 3)	(33)	(1,757)
Net loss after deemed dividend	$ (5,254)	$ (6,325)
Weighted average shares outstanding - basic (in shares)	4,212,000	548,000
Weighted average shares outstanding - diluted (in shares)	4,212,000	548,000
Basic loss per share (in dollars per share)	$ (1.25)	$ (11.54)
Diluted loss per share (in dollars per share)	$ (1.25)	$ (11.54)
March 2020 Offering [Member]
Loss per share [Abstract]
Net deemed dividends resulting from subsequent reduction in exercise price of warrants	$ 200
March 2021 Offering [Member]
Loss per share [Abstract]
Net deemed dividends resulting from subsequent reduction in exercise price of warrants	$ 33
Warrants to Purchase Common Stock [Member]
Potential shares of common stock that are not included in the calculation of diluted net loss per share [Abstract]
Potential shares of common stock that are not included in the calculation of diluted net loss per share (in shares)	1,631,882	925,869
Series H Convertible Preferred Stock [Member]
Potential shares of common stock that are not included in the calculation of diluted net loss per share [Abstract]
Potential shares of common stock that are not included in the calculation of diluted net loss per share (in shares)	0	16,264
Series F Convertible Preferred Stock [Member]
Potential shares of common stock that are not included in the calculation of diluted net loss per share [Abstract]
Potential shares of common stock that are not included in the calculation of diluted net loss per share (in shares)	23,114	48,720
Stock Options [Member]
Potential shares of common stock that are not included in the calculation of diluted net loss per share [Abstract]
Potential shares of common stock that are not included in the calculation of diluted net loss per share (in shares)	140,471	13,995

Shareholders' Equity (Details) $ / shares in Units, $ in Thousands											3 Months Ended	12 Months Ended
	Mar. 19, 2021 USD ($) $ / shares shares	Aug. 21, 2020 USD ($) $ / shares shares	May 05, 2020 USD ($) $ / shares shares	Apr. 01, 2020 USD ($) shares	Mar. 23, 2020 USD ($) $ / shares shares	Jan. 28, 2020 USD ($) $ / shares shares	Nov. 06, 2019 USD ($) $ / shares shares	Oct. 25, 2019 USD ($) $ / shares shares	Mar. 12, 2019 USD ($) $ / shares shares	Nov. 27, 2017 USD ($) $ / shares shares	Mar. 31, 2021 USD ($) $ / shares shares	Dec. 31, 2020 shares	Dec. 31, 2019 shares	Apr. 02, 2020 $ / shares shares	May 30, 2019 $ / shares shares	Jul. 03, 2018 $ / shares
Class of Stock Disclosures [Abstract]
Net proceeds from issuance of convertible preferred stock \| $	$ 57,600
Warrants to purchase shares of common stock (in shares)						585,460	40,638	19,196
Warrants exercised to purchase common stock (in shares)											130,246
Exercise price of warrants (in dollars per share) \| $ / shares					$ 11.18	$ 16.50	$ 29.83	$ 42.30
Preferred stock, shares outstanding (in shares)											0	0
Issuance of common stock, net (in shares)						201,546	40,637	19,195
Public offering price (in dollars per share) \| $ / shares							$ 33.60	$ 34.50
Gross proceeds from public stock offering \| $						$ 9,700	$ 1,360	$ 660
Net proceeds from public stock offering \| $						8,600
Down-round protection in connection with re-pricing of warrants \| $						200
Beneficial conversion amount \| $						$ 1,600
Warrant expiry period					5 years 6 months		5 years	5 years
Warrants exercisable period					6 months			6 months
Expected Stock Price Volatility [Member]
Class of Stock Disclosures [Abstract]
Warrants measurement input											1.3621
March 2019 Offering [Member]
Class of Stock Disclosures [Abstract]
Issuance of common stock, net (in shares)									15,173
Public offering price (in dollars per share) \| $ / shares									$ 157.50
January 2020 Offering [Member]
Class of Stock Disclosures [Abstract]
Exercise price of warrants (in dollars per share) \| $ / shares	$ 5.50
March 2020 Offering [Member]
Class of Stock Disclosures [Abstract]
Warrants to purchase shares of common stock (in shares)					138,715
Exercise price of warrants (in dollars per share) \| $ / shares					$ 9.00
Net deemed dividends resulting from change in exercise price of warrants \| $											$ 200
Issuance of common stock, net (in shares)					138,715
Public offering price (in dollars per share) \| $ / shares					$ 9.00
Gross proceeds from public stock offering \| $					$ 1,200
Net proceeds from public stock offering \| $					$ 1,000
April 2020 Offering [Member]
Class of Stock Disclosures [Abstract]
Warrants to purchase shares of common stock (in shares)														85,506
Exercise price of warrants (in dollars per share) \| $ / shares														$ 11.15
Issuance of common stock, net (in shares)				171,008
Public offering price (in dollars per share) \| $ / shares														$ 13.02
Gross proceeds from public stock offering \| $				$ 2,200
Warrant expiry period				5 years 6 months
May 2020 Offering [Member]
Class of Stock Disclosures [Abstract]
Warrants to purchase shares of common stock (in shares)			59,966
Exercise price of warrants (in dollars per share) \| $ / shares			$ 12.30
Issuance of common stock, net (in shares)			119,930
Public offering price (in dollars per share) \| $ / shares			$ 14.18
Gross proceeds from public stock offering \| $			$ 1,700
Warrant expiry period			5 years 6 months
August 2020 Offering [Member]
Class of Stock Disclosures [Abstract]
Issuance of common stock, net (in shares)		1,064,678
Public offering price (in dollars per share) \| $ / shares		$ 13.50
Gross proceeds from public stock offering \| $		$ 14,400
Net proceeds from public stock offering \| $		$ 13,000
Number of shares issuable on the exercise of warrants (in shares)		1,064,678
Warrant expiry period											5 years
March 2021 Offering [Member]
Class of Stock Disclosures [Abstract]
Net deemed dividends resulting from change in exercise price of warrants \| $											$ 33
Issuance of common stock, net (in shares)	3,795,816
Gross proceeds from public stock offering \| $	$ 20,900
Net proceeds from public stock offering \| $	$ 18,900
Warrants to Purchase Common Stock [Member]
Class of Stock Disclosures [Abstract]
Number of warrants vested (in shares)											0
Warrants to Purchase Common Stock [Member] \| Consultant [Member]
Class of Stock Disclosures [Abstract]
Warrants to purchase shares of common stock (in shares)															3,334
Exercise price of warrants (in dollars per share) \| $ / shares											$ 57.90				$ 95.40
Series F Convertible Preferred Stock [Member]
Class of Stock Disclosures [Abstract]
Gross proceeds from issuance of convertible preferred stock \| $										$ 18,000
Net proceeds from issuance of convertible preferred stock \| $										$ 16,200
Conversion price (in dollars per share) \| $ / shares					$ 9.00	$ 16.50	$ 29.83	$ 42.30	$ 157.50	$ 1,890.00						$ 890.40
Number of consecutive trading days considered for expiration											20 days
Number of consecutive trading days											30 days
Preferred stock issued (in shares)										18,000	127	127
Number of shares issuable on conversion of preferred stock (in shares)										9,557
Preferred stock, shares outstanding (in shares)											127	127
Aggregate cash placement fee									8.00%
Series F Convertible Preferred Stock [Member] \| Minimum [Member]
Class of Stock Disclosures [Abstract]
Percentage of volume weighted average price of common stock										300.00%
Trading volume for each trading day \| $										$ 200
Series F Convertible Preferred Stock [Member] \| January 2020 Offering [Member]
Class of Stock Disclosures [Abstract]
Exercise price of warrants (in dollars per share) \| $ / shares											$ 9.00
Series F Convertible Preferred Stock [Member] \| March 2021 Offering [Member]
Class of Stock Disclosures [Abstract]
Conversion price (in dollars per share) \| $ / shares											5.50
Exercise price of warrants (in dollars per share) \| $ / shares											$ 5.50
Series F Convertible Preferred Stock [Member] \| Warrants to Purchase Common Stock [Member]
Class of Stock Disclosures [Abstract]
Warrants to purchase shares of common stock (in shares)										19,122
Series F Convertible Preferred Stock [Member] \| Warrant Series 1 [Member]
Class of Stock Disclosures [Abstract]
Warrants to purchase shares of common stock (in shares)										16
Exercise price of warrants (in dollars per share) \| $ / shares										$ 1,890.00
Series F Convertible Preferred Stock [Member] \| Warrant Series 2 [Member]
Class of Stock Disclosures [Abstract]
Warrants to purchase shares of common stock (in shares)										16
Exercise price of warrants (in dollars per share) \| $ / shares										$ 1,890.00
Series G Convertible Preferred Stock [Member]
Class of Stock Disclosures [Abstract]
Gross proceeds from issuance of convertible preferred stock \| $									$ 12,400
Net proceeds from issuance of convertible preferred stock \| $									$ 11,000
Conversion price (in dollars per share) \| $ / shares									$ 157.50
Number of consecutive trading days											30 days
Preferred stock, shares outstanding (in shares)													0
Beneficial conversion amount \| $											$ 4,500
Beneficial ownership limitation									4.99%
Conversion of preferred stock into common stock (in shares)													63,685
Series G Convertible Preferred Stock [Member] \| March 2019 Offering [Member]
Class of Stock Disclosures [Abstract]
Number of shares issuable on conversion of preferred stock (in shares)									1,910,536
Series G Convertible Preferred Stock [Member] \| Warrant Series 1 [Member]
Class of Stock Disclosures [Abstract]
Exercise price of warrants (in dollars per share) \| $ / shares									$ 157.50
Number of shares issuable on the exercise of warrants (in shares)									78,863
Series G Convertible Preferred Stock [Member] \| Warrant Series 2 [Member]
Class of Stock Disclosures [Abstract]
Exercise price of warrants (in dollars per share) \| $ / shares									$ 157.50
Number of shares issuable on the exercise of warrants (in shares)									78,863
Series H Preferred Stock [Member]
Class of Stock Disclosures [Abstract]
Conversion price (in dollars per share) \| $ / shares						$ 16.50
Preferred stock, shares outstanding (in shares)												0
Issuance of common stock, net (in shares)						11,517,269
Public offering price (in dollars per share) \| $ / shares						$ 16.50
Maximum percentage of the applicable Unit offering price, by which exercise price can be lower than adjustment						10.00%
Conversion of preferred stock into common stock (in shares)												11,517,269

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Mar. 31, 2021	Dec. 31, 2020
Stockholders' equity
Preferred stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Preferred stock, shares authorized (in shares)	39,969,873	39,969,873
Preferred stock, shares outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Common stock, shares authorized (in shares)	100,000,000	100,000,000
Common stock, shares issued (in shares)	6,531,942	2,736,060
Common stock, shares outstanding (in shares)	6,531,942	2,736,060
Series A Junior Participating Preferred Stock [Member]
Stockholders' equity
Preferred stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Preferred stock, shares authorized (in shares)	30,000	30,000
Preferred stock, shares outstanding (in shares)	0	0
Series F Convertible Preferred Stock [Member]
Stockholders' equity
Preferred stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Preferred stock, shares authorized (in shares)	127	127
Preferred stock, shares issued (in shares)	127	127
Preferred stock, shares outstanding (in shares)	127	127

Revenue Recognition	3 Months Ended
Revenue Recognition	Mar. 31, 2021
Revenue Recognition [Abstract]
Revenue Recognition	Note 2 – Revenue Recognition Net Sales: The Company sells its products in the United States primarily through a direct sales force. Customers who purchase the Company’s products include hospitals and clinics throughout the United States. In countries outside the United States, the Company sells its products through a limited number of specialty healthcare distributors in Austria, Brazil, Brunei, Germany, Greece, Hong Kong, India, Israel, Italy, Palestine, Singapore, Spain, Switzerland, Thailand and the United Kingdom. These distributors resell the Company’s products to hospitals and clinics in their respective geographies. Revenue from product sales are recognized when the customer or distributor obtains control of the product, which occurs at a point in time, most frequently upon shipment of the product or receipt of the product, depending on shipment terms. The Company’s standard shipping terms are FOB shipping point, unless the customer requests that control and title to the inventory transfer upon delivery. Revenue is measured as the amount of consideration we expect to receive, adjusted for any applicable estimates of variable consideration and other factors affecting the transaction price, which is based on the invoiced price, in exchange for transferring products. All revenue is recognized when the Company satisfies its performance obligations under the contract. The majority of the Company’s contracts have a single performance obligation and are short term in nature. The Company has entered into extended service plans with customers which are recognized over time. This revenue represents less than 1% of net sales for the three months ended March 31, 2021 and 2020. The unfulfilled performance obligations related to these extended service plans is included in deferred revenue, which is included in other current liabilities on the consolidated balance sheets. The majority of the deferred revenue is expected to be recognized within one year. Sales taxes and value added taxes in foreign jurisdictions that are collected from customers and remitted to governmental authorities are accounted for on a net basis and therefore are excluded from net sales. Revenue includes shipment and handling fees charged to customers. Shipping and handling costs associated with outbound freight after control over a product has transferred to a customer are accounted for as a fulfillment cost and are included in cost of goods sold. Product Returns: The Company offers customers a limited right of return for its product in case of non-conformity or performance issues. The Company estimates the amount of its product sales that may be returned by its customers and records this estimate as a reduction of revenue in the period the related product revenue is recognized. The Company currently estimates product return liabilities using available industry data and its own historical sales and returns information. The Company has not received any returns to date and believes that future returns of its products will be minimal. Therefore, revenue recognized is not currently impacted by variable consideration related to product returns.

Income Taxes	3 Months Ended
Income Taxes	Mar. 31, 2021
Income Taxes [Abstract]
Income Taxes	Note 5 – Income Taxes The Company provides for a valuation allowance when it is more likely than not that it will not realize a portion of the deferred tax assets. The Company has established a full valuation allowance for U.S. and foreign deferred tax assets due to the uncertainty that enough taxable income will be generated in those taxing jurisdictions to utilize the assets. Therefore, the Company has not reflected any benefit of such deferred tax assets in the accompanying condensed consolidated financial statements. As of March 31, 2021, there were no material changes to what the Company disclosed regarding tax uncertainties or penalties in its Annual Report on Form 10-K for the year ended December 31, 2020.

Finance Lease Liability	3 Months Ended
Finance Lease Liability	Mar. 31, 2021
Finance Lease Liability [Abstract]
Finance Lease Liability	Note 6—Finance Lease Liability In 2020, the Company entered into lease agreements to finance equipment valued at $98,000. The equipment consisted of computer hardware and audio-visual equipment and is included in Property, Plant and Equipment in the accompanying consolidated financial statements. The principal amount under the lease agreements was $93,000 at the date the lease commenced, the implied interest rate is 7.5%, and the term of the lease is 39 months.

Commitments and Contingencies	3 Months Ended
Commitments and Contingencies	Mar. 31, 2021
Commitments and Contingencies [Abstract]
Commitments and Contingencies	Note 7—Commitments and Contingencies Employee Retirement Plan: The Company has a 401(k)-profit sharing plan that provides retirement benefit to substantially all full-time U.S. employees. Eligible employees may contribute a percentage of their annual compensation, subject to Internal Revenue Service (“IRS”) limitations, with the Company matching a portion of the employee’s contributions at the discretion of the Company.

Subsequent Events	3 Months Ended
Subsequent Events	Mar. 31, 2021
Subsequent Events [Abstract]
Subsequent Events	Note 8—Subsequent Events Departure of Claudia Drayton and Appointment of Paul Wotta: On April 1, 2021, Claudia Drayton notified the Company of her decision to resign as the Company’s Chief Financial Officer. On April 5, 2021, the Board of Directors (the “Board”) of the Company appointed Nestor Jaramillo, Jr., the Company’s current President and Chief Executive Officer, as the interim Chief Financial Officer, and Paul Wotta, the Company’s Corporate Controller, as the Company’s interim Principal Accounting Officer. Mr. Jaramillo has served as the Company’s President and Chief Executive Officer since January 2021. Mr. Wotta has served as the Company’s Corporate Controller since December 2011. Name Change: On April 27, 2021, the Company changed its name from CHF Solutions, Inc. to Nuwellis, Inc. to more appropriately reflect the direction of its business.

Revenue Recognition (Details)	3 Months Ended
Revenue Recognition (Details)	Mar. 31, 2021	Mar. 31, 2020
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2021-04-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Abstract]
Expected timing of satisfaction, period	1 year
Sales Revenue [Member] \| Customer Concentration Risk [Member] \| ASC 606 [Member] \| Maximum [Member]
Revenue, Performance Obligation [Abstract]
Percentage of net sales	1.00%	1.00%

Stock-Based Compensation (Details) - USD ($) $ in Thousands	3 Months Ended
Stock-Based Compensation (Details) - USD ($) $ in Thousands	Mar. 31, 2021	Mar. 31, 2020
Stock-Based Compensation Expense Items [Abstract]
Stock-based compensation expense	$ 355	$ 380
Selling, General and Administrative Expense [Member]
Stock-Based Compensation Expense Items [Abstract]
Stock-based compensation expense	327	354
Research and Development Expense [Member]
Stock-Based Compensation Expense Items [Abstract]
Stock-based compensation expense	$ 28	$ 26

Finance Lease Liability (Details) $ in Thousands	12 Months Ended
Finance Lease Liability (Details) $ in Thousands	Dec. 31, 2020 USD ($)
Finance Lease Liability [Abstract]
Value of finance lease equipment	$ 98
Principal amount under lease agreement	$ 93
Implied interest rate	7.50%
Finance lease term	39 months